Table 3.
Treatment | ALT (U/L) | AST (U/L) | ALP (U/L) | γ-GT (nM/min/mg protein) | P53 | CYP 2E1 |
---|---|---|---|---|---|---|
Control | 32.17±2.12† | 83.83±2.74† | 248.00±3.93† | 70.50±2.23† | 48.3±2.38† | 28.0±2.8† |
DMSO+olive oil | 32.50±2.05† | 84.67±2.75† | 249.67±3.68† | 71.33±2.04† | 49±2.03† | 29±5.0† |
3 ml/kg CCl4 | 91.33±3.42** | 228.00±4.27** | 505.33±6.49** | 119.33±3.12** | 27.6±2.46** | 17.1±2.0** |
100 mg/kg LPEE+CCl4 | 77.67±3.36**† | 140.83±3.24**† | 388.33±3.83**† | 106.50±3.77**† | 53±3.78**† | 28±1.2**† |
200 mg/kg LPEE+CCl4 | 38.17±2.77† | 102.17±3.96**† | 262.00±2.37† | 78.33±3.30† | 57±2.63*† | 30±2.3*† |
200 mg/kg LPEE alone | 35.67±3.01† | 98.15±2.12† | 248.12±2.89† | 71.43±5.10† | 49±1.61† | 29±3.0† |
Mean±SE (n=6 number).
Significance from the control group at P<0.05 and P<0.01 probability levels.
Significance from the CCl4 group at P<0.01 probability level.